Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients
Lymphoma is a cancer that begins in the lymphocyte cells of the immune system. There are over 60 different types, broadly grouped into Hodgkin lymphomas and non-Hodgkin lymphomas. Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin lymphoma. The primary treatment for DLBCL...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Student Research Poster |
| Language: | English |
| Published: |
Nanyang Technological University
2023
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10356/170727 |
| _version_ | 1826130119250411520 |
|---|---|
| author | Vijay, Varsheni |
| author2 | Li Yinghui |
| author_facet | Li Yinghui Vijay, Varsheni |
| author_sort | Vijay, Varsheni |
| collection | NTU |
| description | Lymphoma is a cancer that begins in the lymphocyte cells of the immune system. There are over 60 different types, broadly grouped into Hodgkin lymphomas and non-Hodgkin lymphomas. Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin lymphoma. The primary treatment for DLBCL is R-CHOP (Rituximab, Cyclophosphamide, doxorubicin hydrochloride (Hydroxy daunomycin), Oncovin, and Prednisone) chemotherapy. However, even after the treatment, only 50-60% of patients show complete response; the remaining patients suffer from progression in the form of relapse (cancer reappearing) and refractory disease (cancer stops responding to treatment). |
| first_indexed | 2024-10-01T07:51:18Z |
| format | Student Research Poster |
| id | ntu-10356/170727 |
| institution | Nanyang Technological University |
| language | English |
| last_indexed | 2024-10-01T07:51:18Z |
| publishDate | 2023 |
| publisher | Nanyang Technological University |
| record_format | dspace |
| spelling | ntu-10356/1707272023-10-02T15:39:30Z Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients Vijay, Varsheni Li Yinghui School of Biological Sciences liyh@ntu.edu.sg Science::Biological sciences Lymphoma is a cancer that begins in the lymphocyte cells of the immune system. There are over 60 different types, broadly grouped into Hodgkin lymphomas and non-Hodgkin lymphomas. Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin lymphoma. The primary treatment for DLBCL is R-CHOP (Rituximab, Cyclophosphamide, doxorubicin hydrochloride (Hydroxy daunomycin), Oncovin, and Prednisone) chemotherapy. However, even after the treatment, only 50-60% of patients show complete response; the remaining patients suffer from progression in the form of relapse (cancer reappearing) and refractory disease (cancer stops responding to treatment). 2023-09-27T12:55:15Z 2023-09-27T12:55:15Z 2022 Student Research Poster Vijay, V. (2022). Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients. Student Research Poster, Nanyang Technological University, Singapore. https://hdl.handle.net/10356/170727 https://hdl.handle.net/10356/170727 en © 2022 The Author(s). application/pdf Nanyang Technological University |
| spellingShingle | Science::Biological sciences Vijay, Varsheni Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients |
| title | Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients |
| title_full | Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients |
| title_fullStr | Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients |
| title_full_unstemmed | Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients |
| title_short | Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients |
| title_sort | identifying gene signatures contributing to progression after chemotherapy in dlbcl patients |
| topic | Science::Biological sciences |
| url | https://hdl.handle.net/10356/170727 |
| work_keys_str_mv | AT vijayvarsheni identifyinggenesignaturescontributingtoprogressionafterchemotherapyindlbclpatients |